Mylan Selected as a Leading ARV Supplier to India's National AIDS Control Organization
HYDERABAD, India and PITTSBURGH, Sept. 4, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Laboratories Limited has been selected as a leading supplier of antiretroviral (ARV) drugs to India's National AIDS Control Organization (NACO). NACO is a division of India's Ministry of Health and Family Welfare and is responsible for overseeing HIV/AIDS control programs in India. NACO's objective is to halt and reverse the HIV/AIDS epidemic in India over the next five years through integrated programs for prevention, care and support and treatment. NACO manages 35 HIV Prevention and Control Societies, which implement NACO's programs at the State level and manage more than 350 ARV treatment centers.
Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, and helping to ensure access to high quality, affordable ARVs is a core part of this mission. Only through access to these vital medicines can we stem the tide of HIV/AIDS in India and around the world. We are honored that Mylan has been selected as a significant supplier to NACO and look forward to helping this critical organization achieve its mission."
Approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and Mylan has recently entered the Indian commercial market, starting with a portfolio of ARV drugs. Mylan's wide range of ARV products includes active pharmaceutical ingredients and 43 first- and second-line finished doses, nine of which are pediatric products.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.